SGHT - NASDAQ
Sight Sciences, Inc.
$4.34
-4.4%Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
At a Glance
Live SnapshotSight Sciences, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Sight Sciences, Inc. Income Statement
SGHT • NASDAQ
| Sight Sciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
77.4M | 79.9M | 81.1M | 71.3M | 49M | 27.6M | 23.3M | 7.5M | |
GROSS PROFIT | ||||||||
(10.7M) | (11.6M) | (11.9M) | (12.4M) | (8.6M) | (9.2M) | (6.5M) | (2.3M) | |
66.7M | 68.3M | 69.2M | 59M | 40.3M | 18.4M | 16.8M | 5.2M | |
OPERATING INCOME | ||||||||
(103.8M) | (118.8M) | (126.4M) | (142.9M) | (91.8M) | (50.6M) | (40.8M) | (19.5M) | |
(89.2M) | (100.8M) | (108.9M) | (120.1M) | (76.2M) | (41.7M) | (32.7M) | (14.1M) | |
(14.6M) | (18M) | (17.6M) | (22.9M) | (15.6M) | (8.9M) | (8.1M) | (5.4M) | |
-37.1M | -50.5M | -57.3M | -84M | -51.5M | -32.2M | -24M | -14.3M | |
PRE-TAX INCOME | ||||||||
(5.1M) | (4.7M) | (5.4M) | (4.5M) | (4.4M) | (2.4M) | (2M) | (0.0) | |
-1.2M | -4.7M | -5.4M | -4.5M | -4.4M | -2.4M | -1.8M | 1K | |
-1.3M | -739K | 1.8M | -2.2M | -11.3M | -2.4M | -1.8M | 1K | |
-38.4M | -51.3M | -55.4M | -86.2M | -62.8M | -34.6M | -25.9M | -14.3M | |
NET INCOME | ||||||||
(10K) | (236K) | (110K) | (47K) | (188K) | (61K) | (8K) | -6K | |
-38.4M | -51.5M | -55.5M | -86.2M | -63M | -34.7M | -25.9M | -14.3M |
SEC Filings
SGHT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 22, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 03, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your SGHT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.